CASP3 and plasma cell myeloma: Together, the results of the Annexin V apoptosis assay, caspase-3/7 activity assay, and immunoblots for cleaved caspase-3 and PARP make it likely that the observed reduction in viability seen in multiple myeloma cells treated with cPLA2α inhibitors is due to induction of apoptosis.